- Home
- JANX vs CSWC Comparison
JANX vs CSWC Comparison
Compare JANX & CSWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- CSWC
- Stock Information
- Founded
- JANX 2017
- CSWC 1961
- Country
- JANX United States
- CSWC United States
- Employees
- JANX N/A
- CSWC N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- CSWC Textiles
- Sector
- JANX Health Care
- CSWC Consumer Discretionary
- Exchange
- JANX Nasdaq
- CSWC Nasdaq
- Market Cap
- JANX 1.4B
- CSWC 1.3B
- IPO Year
- JANX 2021
- CSWC N/A
- Fundamental
- Price
- JANX $23.15
- CSWC $21.96
- Analyst Decision
- JANX Strong Buy
- CSWC Buy
- Analyst Count
- JANX 11
- CSWC 5
- Target Price
- JANX $76.55
- CSWC $23.70
- AVG Volume (30 Days)
- JANX 714.6K
- CSWC 556.0K
- Earning Date
- JANX 11-05-2025
- CSWC 10-27-2025
- Dividend Yield
- JANX N/A
- CSWC 11.42%
- EPS Growth
- JANX N/A
- CSWC N/A
- EPS
- JANX N/A
- CSWC 1.64
- Revenue
- JANX $439,000.00
- CSWC $209,032,000.00
- Revenue This Year
- JANX N/A
- CSWC $14.60
- Revenue Next Year
- JANX $130.50
- CSWC $10.75
- P/E Ratio
- JANX N/A
- CSWC $13.62
- Revenue Growth
- JANX N/A
- CSWC 10.52
- 52 Week Low
- JANX $21.73
- CSWC $17.46
- 52 Week High
- JANX $71.71
- CSWC $25.90
- Technical
- Relative Strength Index (RSI)
- JANX 48.91
- CSWC 37.80
- Support Level
- JANX $21.73
- CSWC $22.61
- Resistance Level
- JANX $24.54
- CSWC $22.75
- Average True Range (ATR)
- JANX 1.07
- CSWC 0.38
- MACD
- JANX -0.06
- CSWC -0.08
- Stochastic Oscillator
- JANX 47.38
- CSWC 11.62
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CSWC Capital Southwest Corporation
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.